Fortress Biotech Forms New Subsidiary, Cellvation, Inc., to Develop Novel Therapies for the Treatment of Traumatic Brain Injury Nov 07, 2016
Journey Medical Corporation Launches Targadox™ Oral Immediate-Release Tablet for Treatment of Severe Acne Oct 17, 2016
Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 – A Novel Third-Generation EGFR Inhibitor Oct 03, 2016
Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference Sep 23, 2016
Checkpoint Therapeutics Announces Acceptance of IND Application for CK-101 – A Novel Third Generation EGFR Inhibitor Aug 11, 2016
Fortress Biotech Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights Aug 09, 2016
Journey Medical Corporation Launches Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion Jul 25, 2016
Jubilant Biosys Enters into Exclusive out-Licensing Agreement with Checkpoint Therapeutics for Novel BET Inhibitors May 27, 2016
Fortress Biotech Presents Positive Data from the Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia at the Innate Killer Summit 2016 May 18, 2016
